VanEck Bitcoin Trust Common Shares of Beneficial Interest (BATS: HODL)

에 대한 최신 뉴스 VanEck Bitcoin Trust Common Shares of Beneficial Interest (BATS:HODL)

The Trust is a passive investment vehicle that does not seek to generate returns beyond tracking the price of bitcoin.

VanEck Bitcoin Trust

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

ETFs

$BTC

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

BITO

HODL

&#39;부자 아빠와 가난한 아빠&#39;로 유명한 저자인 로버트 기요사키(Robert Kiyosaki)는 월스트리트의 금융 상품보다 자산의 직접 소유권을 선호하면서 비트코인(CRYPTO:BTC)  ​ETF에 대한 무관심을 표명했다. 오늘의 이슈 (What Happened): 목요일, 기요사키는 비트코인 ​​ETF에 대한 관심에 대한 질문에 답하기 위해 트위터를 방문했다. 그는 &#34;아니요. 제가 금화와 은화, 광산, 아파트를 소유하고 있는 것처럼 금, 은 ETF나 REITS, 부동산 ETF를 소유하고 있지 않다.&#34;

로버트 기요사키는 비트코인 ETF에 대해 &#39;노&#39;라고 하며, 월가의 금융 상품들과 거리 유지

VanEck Bitcoin Trust Common Shares of Beneficial Interest

Zelman &amp; Assoc analyst Jesse Lederman downgrades Hovnanian Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOV#NYSE">HOV</a>) from Neutral to Underperform.

News

Downgrades

Analyst Ratings

Zelman & Assoc Downgrades Hovnanian Enterprises to Underperform

Morgan Stanley analyst Toni Kaplan maintains S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Overweight and raises the price target from $595 to $600.

Price Target

SPGI

Morgan Stanley Maintains Overweight on S&P Global, Raises Price Target to $600

Morgan Stanley analyst Keith Weiss maintains Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) with a Overweight and raises the price target from $126 to $144.

SHOP

Morgan Stanley Maintains Overweight on Shopify, Raises Price Target to $144

American International Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) shares are trading lower today. On Tuesday, the company reported that the fourth quarter adjusted EPS of&nbsp;$1.30&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43640648/aig-reports-outstanding-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">exceeded the consensus of $1.23</a>.
Piper Sandler analyst Paul Newsome writes that results came in above consensus but slightly below his estimates due to weaker <a target="_blank" href="https://www.benzinga.com/quote/aig/analyst-ratings" rel="noreferrer noopener">underwriting results and higher expenses</a>.
However, catastrophe losses were in line with his expectations and better than consensus, adds the analyst.
Notably, he notes that AIG reported a 92.5% combined ratio, better than consensus (93.3%) but slightly above his estimate of 91.5%.
Despite some segment noise, the company avoided broader casualty issues, adds the analyst.
Overall, Newsome says investors will view the results as better than expected.
Keefe, Bruyette &amp; Woods analyst Meyer Shields notes that AIG&#8217;s fourth-quarter operating EPS beat their $1.09 estimate, led by stronger core and catastrophe loss ratios, reserve releases and investment income, partially offset by higher expenses and taxes.
The analyst expects shares to gain on the EPS beat and reaffirmed the 10%+ ROE target for 2025, though gains may be tempered by a higher-than-expected expense ratio.
Investors can gain exposure to the stock via Invesco KBW Property &amp; Casualty Insurance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBWP#NASDAQ">KBWP</a>) and iShares U.S. Insurance ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAK#NYSE">IAK</a>).
Price Action: AIG shares are down 1.49% at $74.81 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/42933396/californias-10-trillion-property-market-faces-unprecedented-threat-from-wildfires" target="_blank" rel="noreferrer noopener">California&#8217;s $10 Trillion Property Market Faces Unprecedented Threat From Wildfires</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

iShares Dow Jones US Insurance Index Fund

KBWP

Analysts See AIG's Q4 As Positive, But Expense Ratio Limits Stock Gains

Morgan Stanley analyst Joshua Pokrzywinski maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Overweight and raises the price target from $335 to $345.

Morgan Stanley Maintains Overweight on Rockwell Automation, Raises Price Target to $345

Macro Economic Events

Economics

Federal Reserve

Fed's Goolsbee Says If We Got Multiple Months Like This (On CPI Inflation, Then The Job Is Clearly Not Done)

Morgan Stanley analyst Alex Poon maintains NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) with a Overweight and raises the price target from $108 to $117.

NTES

Morgan Stanley Maintains Overweight on NetEase, Raises Price Target to $117

Morgan Stanley analyst Sanjit Singh maintains Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Equal-Weight and raises the price target from $30 to $32.

CFLT

Morgan Stanley Maintains Equal-Weight on Confluent, Raises Price Target to $32

Citigroup analyst Steven Enders maintains BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) with a Buy and lowers the price target from $73 to $70.

Citigroup Maintains Buy on BlackLine, Lowers Price Target to $70

MiNK Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming&nbsp;American Association for Cancer Research (AACR) IO Annual Meeting that will take place on&nbsp;February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company's ongoing Phase 2 study testing AgenT-797 in combination with Agenus' lead therapeutic combination, botensilimab and balstilimab (BOT/BAL), in patients with refractory (2L+) gastric cancer (<a href="https://www.globenewswire.com/Tracker?data=t6txOKgp_MgEu4o8gN9EhC8-aPrKqm-f_6rS_BW7tVdkK00bmuNqJAGLdL_BAlX-0LUj7fqSq4pXWnarGuDxoySa8PvggMqTPCB8tryykvE=">NCT06251973</a>).

Biotech

General

INKT

MiNK Therapeutics To Present Updated Data From Phase 2 Study Testing AgenT-797 In Gastric Cancer At AACR IO Annual Meeting

<a href="https://www.globenewswire.com/Tracker?data=RRfz9O6r4fGsE9THQr6YofXWnwlfA4EcG2CrfxhZPi7GP2cKD-RstD59AmdT2vJk0ReK04g74dKxsKQ-a91FYdOC546yGDERB2Iuc5TXa1k=">Red Cat Holdings, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) ("Red Cat"), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, today announced it has entered into an agreement for up to $20 million and closed on the initial tranche of $16.5 Million in debt financing with The Lind Partners, a New York based institutional fund manager ("Lind"). Details of the agreement include:
<ul>
<li>Debt Financing convertible at $16.15 share price</li>
<li>Initial Tranche proceeds of $15 million</li>
<li>1 million warrants exercisable at $15.00 per share non cashless &nbsp;</li>
</ul>
Additionally, Red Cat has applied for $58 million in debt financing from the <a href="https://www.globenewswire.com/Tracker?data=31XzAh54dnto-MDxoRJEw-pG3ON3Z0v5FYpnv-NLc6smewtIUFSZEP0QdbDBtqJKE4vxZ-sqNfTD1jRhVS3jJExWx_7a49m7LDQowXZGAb1Cg_DH-fS4rUKqfBJKSk_Q3QwCsJmlziFWEa58e3COAg==">Department of Defense Office of Strategic Capital</a> (OSC). OSC implements strategies and partnerships to accelerate and scale private investment in critical supply chain technologies needed for national security. They have identified 14 critical technology areas vital to maintaining the United States' national security. These have been grouped into three categories as found in the 2023 National Defense Science and Technology Strategy.
<ul>
<li>Seed Areas of Emerging Opportunity</li>
<li>Effective Adoption Areas</li>
<li>Defense-Specific Areas &nbsp;</li>
</ul>
The investment is expected to provide Red Cat with the working capital needed to scale up production and the ongoing development of its Arachnid Family of Systems, which includes Black Widow&#x2122;, Edge 130, and a new line of FANG&#x2122; First-Person View (FPV) drones. The goal of the Family of Systems is to meet the needs of the U.S. Department of Defense and NATO Allies for drone systems that are low-cost, portable, field repairable, and recoverable.

Financing

RCAT

Red Cat Announces It Has Entered Into An Agreement For Up To $20M And Closed On The Initial Tranche Of $16.5M In Debt Financing With The Lind Partners, A New York Based Institutional Fund Manager

In the last three months, 7 analysts have published ratings on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $284.57, a high estimate of $301.00, and a low estimate of $255.00. Observing a 2.41% increase, the current average has risen from the previous average price target of $277.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1739383265_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$283.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$285.00</td>
<td>$301.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$255.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$288.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$290.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$301.00</td>
<td>$288.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Humana's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Humana's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Humana analyst ratings.</a>
<h2>About Humana</h2>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Humana: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Humana's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.26% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Humana's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.63% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Humana's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.8% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Humana's ROA stands out, surpassing industry averages. With an impressive ROA of 0.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Humana's debt-to-equity ratio stands notably higher than the industry average, reaching 0.74. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Humana Stock: Analyst Perspectives (7 Ratings)

Throughout the last three months, 8 analysts have evaluated Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Myriad Genetics and provided 12-month price targets. The average target is $19.25, accompanied by a high estimate of $29.00 and a low estimate of $13.00. Observing a downward trend, the current average is 23.0% lower than the prior average price target of $25.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1739383256_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Myriad Genetics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Myriad Genetics's Background</h2>
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
<h3>Breaking Down Myriad Genetics's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Myriad Genetics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 11.15%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Myriad Genetics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -10.36% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -3.0%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.04%, the company showcases efficient use of assets and strong financial health.
Debt Management: Myriad Genetics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.2.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MYGN

Expert Outlook: Myriad Genetics Through The Eyes Of 8 Analysts

Trading Ideas

iShares Trust Dow Jones US Healthcare Sector Index Fund

SPOT

CNBC Halftime Report Final Trades: Vertiv, Spotify Technology, iShares U.S. Healthcare ETF

Ratings for Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $78.11, along with a high estimate of $108.00 and a low estimate of $15.00. This upward trend is evident, with the current average reflecting a 48.95% increase from the previous average price target of $52.44.
<img src="https://www.benzinga.com/files/images/story/2025/1739383245_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Upstart Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$15.00</td>
<td>$13.50</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$39.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Simon Clinch</td>
<td>Redburn Atlantic</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$57.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Upstart Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Upstart Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Upstart Hldgs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Upstart Hldgs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UPST/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Upstart Hldgs analyst ratings.</a>
<h2>Discovering Upstart Hldgs: A Closer Look</h2>
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.
<h3>Key Indicators: Upstart Hldgs's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Upstart Hldgs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.5% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -4.17%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Upstart Hldgs's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.14%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Upstart Hldgs's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.37%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Upstart Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 1.58, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UPST

9 Analysts Assess Upstart Hldgs: What You Need To Know

Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $28.0, a high estimate of $32.00, and a low estimate of $24.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.08%. 
<img src="https://www.benzinga.com/files/images/story/2025/1739383236_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Kennametal is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$24.50</td>
</tr>
<tr>
<td>Stephen Volkmann</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$32.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Chris Dankert</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Kennametal. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kennametal compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Kennametal's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Kennametal's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KMT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Kennametal analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Kennametal</h2>
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
<h3>Kennametal's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Kennametal's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.14%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Kennametal's net margin excels beyond industry benchmarks, reaching 4.59%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Kennametal's ROE stands out, surpassing industry averages. With an impressive ROE of 1.75%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Kennametal's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.88% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Kennametal's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.51.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Kennametal In The Eyes Of 5 Experts

TJX Companies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) short percent of float has fallen 13.85% since its last report. The company recently reported that it has 12.57 million shares sold short, which is 1.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.03 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TJX Companies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739383223_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TJX Companies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing TJX Companies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TJX Companies's peer group average for short interest as a percentage of float is 12.74%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into TJX Companies's Recent Short Interest

5 analysts have expressed a variety of opinions on Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $97.2, a high estimate of $109.00, and a low estimate of $89.00. This current average represents a 2.02% decrease from the previous average price target of $99.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1739383219_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Medtronic among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$89.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$97.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$93.00</td>
<td>$96.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Medtronic. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Medtronic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Medtronic's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Medtronic analyst ratings.</a>
<h2>Delving into Medtronic's Background</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>Financial Insights: Medtronic</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Medtronic's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 5.25%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 15.11%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Medtronic's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.63%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Medtronic's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.41%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Medtronic's debt-to-equity ratio surpasses industry norms, standing at 0.58. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Medtronic In The Eyes Of 5 Experts

Trimble's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NYSE">TRMB</a>) short percent of float has risen 10.0% since its last report. The company recently reported that it has 2.84 million shares sold short, which is 1.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Trimble Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739383218_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Trimble has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Trimble's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Trimble's peer group average for short interest as a percentage of float is 7.88%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TRMB

Peering Into Trimble's Recent Short Interest

<a href="https://www.benzinga.com/personal-finance/25/02/43472841/people-first-then-money-then-things-suze-ormans-6-secrets-to-success">Suze Orman</a> has never been shy about her opinions on personal finance, and when it comes to dental insurance, she doesn't hold back. In a <a href="https://omny.fm/shows/suze-ormans-women-and-money/ask-kt-suze-anything-do-the-trump-tariffs-mean-it">recent episode</a> of the Women &amp; Money podcast, Orman made it clear: "It is no secret that I don't like dental insurance." Instead, she and her wife, KT, swear by dental savings plans, which they say offer better value and more flexibility. Here's why.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
</ul>
<h2 class="wp-block-heading">The Downsides of Dental Insurance</h2>
Orman points out several key issues that she has with traditional dental insurance:&nbsp;
<ul>
<li>Expensive premiums – Many plans require monthly premiums that can range from $20-$50 for individuals or $50-$150 for families, sometimes more depending on coverage. </li>
<li>Annual coverage limits – Most policies cap coverage at $1,000 to $2,000 per year. When you have major procedures like root canals, crowns, or dental implants, that limit goes quickly, leaving policyholders to pay the rest out of pocket.</li>
<li>Waiting periods – Many dental insurance plans have <a href="https://www.benzinga.com/money/dental-insurance-waiting-period">waiting periods</a> of a few months to a year before you can receive full coverage for major procedures. </li>
<li>Limited coverage for major work – Preventative and routine care like cleanings and checkups are typically covered 100%, however, more expensive treatments like fillings and crowns often require substantial co-pays or are only partially covered. </li>
</ul>
With these limitations, Orman believes that most people are better suited with a dental savings plan.&nbsp;
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
<h2 class="wp-block-heading">How Dental Savings Plans Work</h2>
Dental savings plans operate on a membership model, rather than using monthly premiums like traditional insurance. Members pay an annual fee, generally around $200, and in return, they receive discounted rates on dental procedures at participating dental offices. Savings typically range from 10% to 60% on various dental procedures.&nbsp;
Orman spoke about her own experience with such plans and how the savings add up quickly, stating that she saves around $1,200 on each root canal procedure–which she needed three of in a two-year period. KT added that she always saves over $1,000 on crowns.
Unlike insurance, dental savings plans don't have an annual cap on savings and members can start using the plan almost immediately after signing up.&nbsp;
See Also: <a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a>
<h2 class="wp-block-heading">Who Benefits Most From A Dental Savings Plan?&nbsp;</h2>
Depending on your individual or family needs, a dental savings plan may not be the best fit for everyone. But they can be a smart choice for:&nbsp;
<ul>
<li>Retirees on Medicare: Traditional <a href="https://www.benzinga.com/personal-finance/25/01/43218719/medicares-at-home-care-and-telehealth-restrictions-in-2025-could-limit-access-to-affordable-healthcare-heres-what-you-need-to-know">Medicare</a> doesn't cover most dental work, so a savings plan can be an affordable alternative. </li>
<li>Uninsured individuals: Those who don't have employer-provided dental insurance can access lower-cost dental care without high premiums. </li>
<li>People with good oral health: If you primarily need preventative care with the occasional filling or crown, a dental savings plan can provide major savings over time. </li>
<li>Families needing major work: If you need to avoid the long waiting periods that insurance may require, a dental savings plan provides immediate discounts for major work. </li>
</ul>
While insurance can still be a good fit for those needing extensive coverage, Orman believes a savings plan can offer more flexibility and affordability for many people.
Before making a decision, take the time to assess your dental needs, compare costs, and consider how often you require dental care. Whether you <a href="https://www.benzinga.com/money/dental-savings-plans-vs-dental-insurance">choose insurance or a savings plan</a>, making an informed choice can help you protect both your teeth and your finances.
Read Next:
<ul>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>This Company Is Launching Major Franchises Featuring Cinderella, Snow White and other billion dollar characters. <a href="https://www.benzinga.com/money/elf-labs-1">Their funding window closes today so take advantage of just $2/share ($980 minimum) Limited shares available</a></li>
</ul>

Personal Finance

'It Is No Secret That I Don't Like Dental Insurance'– Suze Orman Shares Why Dental Savings Plans Are Better

Bitcoin: Torn Between Bull Runs And Bear Plunges, Extreme Volatility Ahead

Cathie Wood sells 36K shares of her own bitcoin-backed ARKB to start off 2025

The Bitcoin Spot ETFs, one of the most exciting financial markets at the moment, closed out another week with net inflows resulting in three consecutive weeks of gains.

Bitcoin Spot ETFs See $1.86 Billion Inflows, Extend 3-Week Positive Streak

Building A 2025 Portfolio: Inflation Hedges And AI Plays

Bitcoin should reach $150,000 says Evercore ISI

Musk discussing blockchain use at Department of Government Efficiency

Trump meme coin 'hysteria' is more 'evidence of froth in asset markets' - Moody's

Trump is fueling a crypto bubble that 'could wreak havoc' – Elliott

Bitcoin, ether sink as Trump tariffs push traders away from risky assets (updated)

Equities, gold or bitcoin? New SEC filing looks to cover it all under one ETF umbrella

ARKF

ARKG

ARKK

ARKW

ARKX

BITB

BITQ

BITW

BITX

BKCH

BLOK

BRRR

BTCO

BTCW

CNXT

CRPT

DAPP

DGIN

DUST

ETHA

ETHE

ETHV

ETHW

EZBC

FBTC

FDIG

FETH

GBTC

GDXJ

GLIN

IBIT

IBLC

MAXI

MOAT

MOTI

NUGT

OUNZ

RING

SDOW

SGOL

SMOT

SPXU

SQQQ

TQQQ

UDOW

UPRO

WGMI

YBTC

Asset Manager VanEck Files To Launch Solana ETF

$ETH

$SOL

&#8216;부자 아빠와 가난한 아빠&#8217;로 유명한 저자인 로버트 기요사키(Robert Kiyosaki)는 월스트리트의 금융 상품보다 자산의 직접 소유권을 선호하면서 비트코인(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/btc-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BTC/USD">BTC</a>)  ​ETF에 대한 무관심을 표명했다.
오늘의 이슈 (What Happened): 목요일, 기요사키는 비트코인 ​​ETF에 대한 관심에 대한 질문에 답하기 위해 트위터를 방문했다. 그는 "아니요. 제가 금화와 은화, 광산, 아파트를 소유하고 있는 것처럼 금, 은 ETF나 REITS, 부동산 ETF를 소유하고 있지 않다."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter">
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Q: Will you buy the Bitcoin ETF? A: No. Just as I own gold and silver coin and mines and own apartment houses I do not own gold or silver ETFs or REITS, real estate ETFS. ETFs are best for most people and institutions. Personally I am an entrepreneur and prefer to stay as far…
— Robert Kiyosaki (@theRealKiyosaki) <a href="https://twitter.com/theRealKiyosaki/status/1778640352444084425?ref_src=twsrc%5Etfw">April 12, 2024</a>
</blockquote>
</div>
</figure>
참고 자료: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38173334/dogecoin-killer-shiba-inus-daily-transactions-spike-1-082-still-very-bullish-on-shib-says-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;도지코인 킬러&#8217; 시바 이누의 1,082% 급증, &#8216;SHIB에 대해 여전히 매우 낙관적&#8217;</a>
기요사키는 자신만의 금융상품 패키지를 선호하는 이유를 추가로 설명하며, 이를 통해 자신이 &#8220;대부분의 ETF 구매자보다 더 똑똑해야 한다&#8221;고 말했다. 그는 자신의 방식이 그에게 가장 잘 맞는 방식이라고 강조했으며, 자신이 실수를 하더라도 자신이 직접 책임져야 한다고 내세웠다.
중요도 (Why It Matters): 기요사키의 비트코인 ETF에 대한 입장은 비트코인에 대한 낙관적인 전망 속에서 이루어졌다. 지난 1월에는 그가 비트코인의 가치가 <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36570286/bitcoin-to-150k-soon-says-rich-dad-poor-dad-author-robert-kiyosaki-in-light-of-potential-b">15만 달러로 상승할 것이라 예측했죠</a>. 그는 또한 현물 ETF 승인 당시 <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36588889/rich-dad-poor-dad-fame-robert-kiyosaki-says-hes-bought-5-more-bitcoin-amid-spot-etf-approv">23만 달러 이상의 가치를 지닌 비트코인 5개</a>를 추가로 구입했다고 공개했다.
2024년 1월 비트코인 ETF 중 프로셰어즈(ProShares)의 비트코인 전략 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITO#NYSE">BITO</a>), VanEck 비트코인 트러스트 (BATS:<a class="ticker" href="https://www.benzinga.com/stock/HODL#BATS">HODL</a>) 및 ARK 21Shares 비트코인 ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>)가 승인을 받았다.
비록 기요사키가 비트코인에 대해 낙관적인 입장을 표현하긴 했지만, 그의 최근 트윗에서는 월스트리트의 금융 상품에서 멀어지는 자산의 직접적 관리를 선호하는 것으로 나타났다.
유독 참고할 점은 기요사키가 아크 인베스트(Ark Invest)의 최고경영자(CEO)인 캐시 우드(Cathie Wood)의 비트코인 230만 달러 예측에 동의했다는 것인데, 그는 <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38196659/rich-dad-poor-dad-author-robert-kiyosaki-echoes-cathie-woods-bold-2-3m-bitcoin-call-says-l">더욱 대담한 투자 방법에 지지를 표명했다</a>. 그는 이에 대해 &#8220;캐시 우드는 매우 똑똑하다. 나는 그의 의견을 신뢰한다&#8221;라고 말했다.
참고: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38152348/jeo-boden-meme-coin-up-more-than-21-spikes-past-1-imagine-when-trump-starts-saying-boden-m?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;제오 보덴&#8217; 코인, 21% 이상 상승하여 1달러 돌파: 트럼프가 &#8216;보덴&#8217;이라 말하기 시작하자</a>



<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

로버트 기요사키는 비트코인 ETF에 대해 '노'라고 하며, 월가의 금융 상품들과 거리 유지

Comments

VanEck Bitcoin Trust Common Shares of Beneficial Interest

뉴스

에 대한 최신 뉴스 VanEck Bitcoin Trust Common Shares of Beneficial Interest (BATS:HODL)

금요일, 4월 12, 2024

뉴스

파트너 / 기고자

벤징가 글로벌